Mr Richard Nagle
Chief Executive Officer
Mr Richard Nagle (Chief Executive Officer) is a life sciences entrepreneur with over 25 years’ experience in the pharmaceutical industry across the US, Europe and Australasia. He was part of the early Innovex HQ team, at the forefront of outsourcing services, where he built and managed the development of large pharmaceutical sales forces, CRA’s and marketing. Innovex was acquired by Quintiles. He was Commercial Director of Walsh/PMSI, which was acquired by IMS Health, the leading supplier of strategic research and data to the pharmaceutical industry.
Moving into drug development, he became Commercial Director of Adelphi Group, responsible for the Strategic Product Development Consultancy, advising global pharmaceutical companies. He was CEO of Cardiac Alert which was acquired by Quintiles. He developed a new drug delivery system for Alza Corporation. The product was subsequently sold to Bayer and is now sold as Duragesic™. He co-founded Melee Venture Management which founded and developed a pain management business, an agri-biotech venture which placed extracted silica into depleted soils in commercial farms, two leading scientifically based cosmetics companies and a wound healing group, Wound Solutions. He joined Metellus, a Swiss-based investment firm, as Partner in 2014, joining the Board of Peptinnovate in 2015.
Dr. Clare Burgess
Chief Operating Officer
Dr. Clare Burgess (Chief Operating Officer) is a pharmacologist who has worked in the pharmaceutical industry for 24 years across a wide range of therapeutic areas. She has a broad knowledge of drug development from candidate selection through to Phase III clinical trials gained through roles at GSK (and legacy companies) as a Toxicology Study Director, Clinical Development Director and Global Project Leader, leading multidisciplinary teams across the USA and Europe. At GSK, Clare was the Clinical leader for an atypical antipsychotic drug taking it from FTIH to Phase 2b. Within this project she completed a Phase 1b safety study in schizophrenia patients (a first at GSK) and delivered one of the first fully adaptive proof of concept studies in patients with acute schizophrenia. Clare also designed and gained EMA endorsement for a first of its kind, thorough QTc study in patients with chronic schizophrenia (an industry first). Prior to joining Peptinnovate as COO, Clare was Head of Development and then COO at Helperby Therapeutics.
Mr David Beadle
Chief Business Officer
David Beadle has over 25 years’ experience in the healthcare and finance industries and brings a wealth of knowledge in investment banking, finance and life sciences. David started his career working in the pharmaceutical industry for Schwarz Pharma and Schering AG in marketing and strategic development, where he was part of the global development group for oncology.
He then moved to investment banking where he built and led highly ranked healthcare equity research teams both globally and across Europe. He first joined Hoare-Govett and then moved to UBS AG investment bank where he was a Managing Director in the equities division. He was a leading and highly ranked equity research analyst in the healthcare sector for over 10 years. At UBS, David was the lead analyst on several corporate finance projects, including IPOs and M&A.
David has been a non-executive Director to two successful companies in the healthcare and biotechnology space and has consulted for many others regarding scientific, corporate finance and business development strategies. David was a founding partner of Napa Capital, a corporate finance advisory company, working with several clients regarding financing projects and corporate strategy.
Mr. Michael Albisser
Director/Chief Financial Officer
Michael Albisser (Chief Financial Officer) was previously acting CFO of the controlling unit of a multi-billion dollar single Family Office in Europe, before joining Metellus as a Partner. Extensive experience in accounting, controlling and reporting of investments in all asset classes, including Private Equity, Hedge Funds, industrial and agricultural ventures.
Prof. Richard Knowles
Chief Scientific Officer
Professor Richard Knowles is a highly experienced and successful as a Drug Discovery Pharmacologist and Biochemist and Director of Clinical Biology, he has a demonstrated ability and track record in evaluating and progressing multiple drug discovery opportunities from target discovery to clinical studies, in the identification of biomarkers to guide clinical development, and as an enthusiastic and empowering leader of multiple teams.
He worked for GSK for 26 years, specialising in translational respiratory and inflammation drug discovery, and leading departments and projects seeking oral, inhaled and injected candidate medicines. This included work on both components of Relvar and on Nucala, both important marketed medicines. Previous experience and publications have covered multiple therapeutic areas including cardiovascular, critical care, metabolism, CNS, cancer and women’s health, as well as a wide range of inflammatory diseases.
Dr. Jeannette Watson
Head of Development
Dr. Jeannette Watson (Head of Development) is a pharmacologist by background and has worked in the pharmaceutical/biotechnology arena for over 25 years. A substantial amount of her career was spent at GSK and its legacy companies, whereby she successfully led CNS projects from target validation to early phase clinical development, through which she gained a good working knowledge of the drug development process.
During her time at GSK, Jeannette was also a key player in the establishment of human native tissue assays for pharmacological assessment of drug candidates in the target tissue. Jeannette then joined the small investor-funded biotech area whereby her first role was to lead the early phase clinical studies for Immune Targeting Systems, a company developing peptide vaccines for infectious diseases. During this period, Jeannette was instrumental in driving the preclinical development and Phase I assessment of a live virus that was subsequently approved for use in Phase II human challenge studies. Prior to joining Peptinnovate as Head of Development, Jeannette was Head of Clinical Project Management at Autifony Therapeutics. During this period, she helped build the clinical development team (both internal and external) to support the execution of the company’s clinical portfolio.
Dr. Donata Federici-Canova
Group Discovery Leader
Dr. Donata Federici-Canova (Group Discovery Leader) is a biotechnologist, with expertise on immunology studies and related inflammatory diseases. She has conducted post-doctoral research on the evaluation of anti-inflammatory properties of chaperonin-derived peptides at the Centre for Biochemical Pharmacology, WHRI, Queen Mary University of London. She holds a PhD in Molecular Medicine from the University of Eastern Piedmont, Italy.
Dr. Ginny Norris
Interim Chief Medical Officer
Dr. Ginny Norris (Interim Chief Medical Officer) is a pharmaceutical physician with 16 years drug development experience across all phases (5 years specialist clinical pharmacology CR0, 11 years pharmaceutical industry), with a special interest in translational/early phase development. She has led a number of multidisciplinary development teams and clinical matrix teams providing strategic leadership to define and execute the overall development and/or clinical plans for assigned assets.
She also has extensive experience in clinical trial design and execution. This includes as an Investigator for numerous phase 1 (including FTIH) and phase 2a studies. She has experience in the development of small molecules (oral and inhaled) and biologics. She has considerable experience working in external collaborations for example with scientific experts, in-licensing and co-development partners. She has had interactions with major regulatory agencies (US, Europe, Japan, Korea) for purposes of scientific advice. Prior to joining Peptinnovate, Ginny was Medical Director at RespiVert Ltd and she has held several senior positions in GSK, most recently as Senior Director, Translational Medicine, Immuno-inflammation TA. Before entering pharmaceutical medicine she spent 6 years in hospital medical practice.
Dr. Ann Simon
Director of Corporate Affairs
Dr Ann Simon has successful track record in the life sciences and technology sectors and has worked with numerous companies providing support and advice in the areas of finance, strategic planning and funding to development-stage life sciences companies. At Peptinnovate, Ann has responsibility for legal, corporate governance and financial planning.
She spent more than a decade in corporate finance advisory at Cazenove & Co. in City of London advising clients ranging from start-ups to FTSE100 companies. She has managed IPOs (London full list and AIM), corporate acquisitions and trade sales and fund raisings in the public and private markets.
Over the past 15 years she has held numerous executive and non-executive roles including chairman of OBS Medical and Chief Financial Officer of Pyreos, mLED, Sphere Medical Holding, Genosis, Mirada Solutions, NextGen Sciences, e-San and Bioglan Pharma. She is currently a non-executive director of Scientific Digital Imaging (where she chairs the audit committee), Spectrum General in connection with the Rainbow Seed Fund and Lumacron. Ann will be initially working with Peptinnovate on a part-time basis.